Drugs / VOY-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06087458 | Jun 2023 → Jun 2027 expected | diffuse secondary choroid atrophy, dry age related macular degeneration | Perceive Biotherapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05380492 | Nov 2022 → Nov 2025 | age-related macular degeneration, diffuse secondary choroid atrophy | Perceive Biotherapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VOY-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06087458 ↗ |
| Route | Intravitreal | “single, unilateral intravitreal (IVT) injection of three dose levels of VOY-101 therapy” NCT05380492 ↗ |